Publication | Closed Access

PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease

Neurodegenerative DiseasesMicroglial ProliferationMedicinePharmacologyNeuropharmacologyBrain-immune InteractionNeuroprotectionNeuroscienceNeurologyPpar-γ Agonist Pioglitazone6-Hydroxydopamine ModelMolecular NeurobiologyNeuroimmunologyNeurochemistryNeuroinflammation